Mateon Therapeutics, Inc.
MATN
MATN was delisted on the 7th of December, 2016.
1 hedge funds and large institutions have $12K invested in Mateon Therapeutics, Inc. in 2021 Q2 according to their latest regulatory filings, with funds opening new positions, 0 increasing their positions, 1 reducing their positions, and closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
45% less capital invested
Capital invested by funds: $22K → $12K (-$10K)
100% less repeat investments, than reductions
Existing positions increased: 0 | Existing positions reduced: 1
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IA
IFP Advisors
Tampa,
Florida
|
-$322 |
MATN Hedge Fund Activity: Q2 2021 in Review
1 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Mateon Therapeutics, Inc. (MATN) for Q2 2021, worth a combined $12K — down 45% from $22K a quarter earlier.
Fund positioning in MATN was balanced in Q2 2021: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 1 trimmed.
The largest seller was IFP Advisors, cutting an estimated $322.
- 1 institutional investor held Mateon Therapeutics, Inc. (MATN) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $12K of Mateon Therapeutics, Inc. stock for Q2 2021, down 45% quarter-over-quarter.
- 0 funds opened new Mateon Therapeutics, Inc. positions in Q2 2021 and 0 closed out.
- The largest Mateon Therapeutics, Inc. seller in Q2 2021 was IFP Advisors, an estimated $322 sold.
Based on aggregated 13F filings for Q2 2021.